RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (February 2016)

34 slides from RespireRx Pharmaceuticals's investor presentation, Feb 4, 2016

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements oN) RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," “anticipates,” "intends," "e

  3. Slide 3: Breath quote

    Breath GQ RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." raves Abbot George Burke

  4. Slide 4: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for Respiratory Diseases RN RespireRx o Two drug platforms o Three Phase 2 or Phase 2-ready programs o Three pre-clinical programs o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for strategic collaboratio

  5. Slide 5: Company Focus

    Company Focus dQ RespireRx Pharmaceuticals Inc o Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines = Semi-acute use — post-surgical pain management with opioids = Acute use — surgical anesthesi

  6. Slide 6: Respiratory Diseases Product Pipeline

    Respiratory Diseases Compound Dronabinol Cx1739 Indication Obstructive Sleep Apnea Central Sleep Apnea Opioidinduced RD Spinal Damage/Pompe Combination Formulation with Opioids for Reduced RD Drug-induced Respiratory Depression (injectable) Product Pipeline Pre-clinical WD RespireRx chee suit Inc

  7. Slide 7: Sleep Apnea

    Sleep Apnea GQ RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed co The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) Gd RespireRx o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stroke, hypertension, he

  9. Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    RespireRx Pharmaceuticals Inc CPAP Efficacy is Severly Limited by Patient Compliance R o Works as an air splint to keep upper airway open during sleep o 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine o Over 50% of patients stop using CPAP in the first year o Many C

  10. Slide 10: Dronabinol: a Breakthrough Treatment for OSA

    Dronabinol: a BreakthroughTreatment for OSA B® RespireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (delta 9)THC, a cannabinoid agonist o Background = Schedule Ill drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients an

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of nabinol in OSA RespireRx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at baseline,

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Dronabinol Proven to Reduce Apnea in OSA Subjects RespireRx Pharmaceuticals Inc Dronabinol P<0.01 Reductionin Sleep Apnea ° & 12

  13. Slide 13: Apnea Suppression as a Function of Time

    Apnea Suppression as a Functi Time RespireRx Pharmaceuticals Inc atstHalf =2ndHalf i ‘ , AAHI versus Baseline BB 5S 8 5 & wk HO n=47 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13

  14. Slide 14: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Ongoing Dronabinol Phase 2B Clinical Trial in OSA (Es RespireRx Pharmaceuticals Inc ° Sponsored and led by U of Illinois 4 major centers, fully funded by NIH ° o Potentially pivotal for an NDAsubmission © 120 subjects (40/group, 6 wks dosing) o Doses: Placebo, 2.5 mg, 10 mg qd o Data expected Q3/201

  15. Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market a RespireRx o License to issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical marijuana

  16. Slide 16: The Dronabinol Opportunity

    The Dronabinol Opportunity AQ RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands pre

  17. Slide 17: Central Sleep Apnea

    Central Sleep Apnea GQ RespireRx o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for the indication 17

  18. Slide 18: The Severity of CSA is Correlated with Increased Mortality in HF Patients

    The Severity of CSA is Correlated with Increased Mortal n HF Patients GQ Resp pireRx Pharmaceuticals Inc 6 AHI less than S per hour ‘eo AHL equal or greater than per hour #888 xo Sal 4 : Reducing Central z 7 ie 1 Sleep Apnea May Se x . % = Reduce Mortality in 2 + Heart Failure Patients + eit Y Pao.0

  19. Slide 19: Ampakines - A Novel Class of Drugs

    AMPAKINES — A NOVEL ASS OF DRUGS BA RespireRx eee Inc AMPA Receptors Mediate Synaptic Transmission in the Brain AMPAKINE o Glutamate is the major excitatory neurotransmitter in ee the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors o Ampakines are positive, allosteric

  20. Slide 20: Ampakines - Novel Treatment for Respiratory Depression

    AMPAKINES - Novel Treatment for Respirat Depres: . WN RespireRx Pharmaceuticals Inc Initial esearch conducted by Dr J. Gi Renet al, Anesthesiology. 110:1364- U. Alberta 1009 ° PreBétzinger PreBotzinger Complex Complex Neurons in this brainstem region control inspiratory breathing rhythm PreBotC neur

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine in Phase 2A

    X1739: A Third Generation, Oral Ampakine in Phase 2 A RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) * Reversal and prevention of opioid-induced Respiratory Depression (RD) = Combination formulation with an opioid for treatment of chronic pain o Stage of Development

  22. Slide 22: CX1739: Completed Phase 2A in Sleep Apnea

    RespireRx sees sobtiin Inc CX1739: Completed Phase 2A in Sleep Apnea Design Randomized, double-blind, placebo-controlled study Population —_| 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of

  23. Slide 23: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas OQ Resp pireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea 3% 6 12 3 5 10. Wes: ts es gE SEs gE E52 25 EG Sil 4 Su2 Sa 4 : : = ; °. 0. 0. om v a x os e eg eg 23

  24. Slide 24: Drug-induced Respiratory Depression

    Drug-induced Respiratory Depression RespireRx RDis the most frequent lethal side effect of opioid use o Acute and Semi-Acute Use of opioids = ~25M patients/year at risk for RD (hospitalized, peri- and post-surgical opioid patients) Chronic Opioid Use = Use of Ampakines in combination with other drug

  25. Slide 25: Two clinical studies in healthy volunteers with CX717

    9 Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil Respiratory and analgesia end-points were measured 25 Pharmaceuticals Inc

  26. Slide 26: CX717 Respiratory Rate Results (Breaths/min)

    Breaths/min a S o > Baseline +Alfentanil NS +Naloxone CoPlacebo mae CX717 *P<0.01 NS - Not Significant 26 Pharmaceuticals Inc

  27. Slide 27: CX717 Pain Sensitivity Results

    it Pharmaceuticals Inc 2.0 (Placebo 4 G@CX717 ig 3 NS 0.0: Baseline +Alfentanil +Naloxone Data are expressedas the pain sensitivity,normalzedto the Baseline measurement N= 1Sand 16 pergroup.CX717 doses 1500mg. 27

  28. Slide 28: Respiratory Diseases Product Pipeline

    Respiratory Diseases Compound Dronabinol Cx1739 Indication Obstructive Sleep Apnea Central Sleep Apnea Opioidinduced RO Spinal Damage/Pompe Combination Formulation with Opioids for Reduced RD Drug-induced Respiratory Depression (injectable) Product Pipeline Pre-clinical RD RespireRx pied odor Inc

  29. Slide 29: Key Objectives for 2016 (Pending Financing)

    Compound Dronabinol CX1739 CX1739 / CX717 CX717 Cx1942 Key Objectives for 2016 (Pending Financing) Indication Obstructive Sleep Apnea Opioid-induced RD Central Sleep Apnea Spinal Cord Injury, Pompe Disease, other Combination formulation with opioid Injectable for RD Status Phase 2B Phase 2A Phase 2A

  30. Slide 30: NIH-Supported Programs in Drug Abuse

    NIH-Supported Programs in Drug Abuse FAR) RespireRx Non-Core Programs in Drug Abuse and Addiction - Cocaine andAmphetamines - Research and development program with NIDA + NIDAcontracts with specialistlabs and pays for animal studies - Company provides compounds and retains all rights 30

  31. Slide 31: Capital Structure

    Capital Structure (in WR RespireRx respite Inc As of September 30, 2015 Common Stock 477,221 Common Stock Equivalents of all Convertibles (Preferred Stock and Convertible Notes) 95,934 Common Stock Equivalents of all Options and 380,247 Warrants Total 953,402 a Closing price per share of Common Stoc

  32. Slide 32: Management and Directors

    Management and Directo A James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director CCO Agile Therapeutics Director CEO C

  33. Slide 33: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for Respiratory Diseases WR RespireRx Pharmaceuticals Inc o Two drug platforms o Three Phase 2 or Phase 2-ready programs o One pre-clinical program o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for strat

  34. Slide 34: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases 34

RespireRx Pharmaceuticals — Investor Presentation (February 2016) on 6ix